Carriage of at least 1 reduced-function CYP2C19 allele was associated with a significantly increased risk of major adverse cardiovascular events in patients on clopidogrel for PCI.
Does carriage of a reduced-function CYP2C19 allele increase the risk of major adverse cardiovascular events in patients treated with clopidogrel for PCI?
Carriage of a reduced-function CYP2C19 allele significantly increases the risk of MACE and stent thrombosis in patients receiving clopidogrel for PCI.
Among patients treated with clopidogrel for percutaneous coronary intervention, carriage of even 1 reduced-function CYP2C19 allele appears to be associated with a significantly increased risk of major adverse cardiovascular events, particularly stent thrombosis.
Mega et al. (2010) studied this question. Carriage of at least 1 reduced-function CYP2C19 allele was associated with a significantly increased risk of major adverse cardiovascular events in patients on clopidogrel for PCI.